On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
BUSINESS
Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
Novo Nordisk Pharma said on March 13 that it has obtained Japanese approval for three types of single-dose subcutaneous devices for its once-weekly GLP-1 agent Ozempic (semaglutide), which has been pending listing since its approval two years ago. Ozempic was…
To read the full story
Related Article
BUSINESS
- Axcelead Chief Says Small-Molecule Drug Targets More than Doubled in Last Few Years; IPO Eyed in 4-5 Years
August 7, 2020
- Sumitomo Dainippon Eyes 100 Billion Yen Sales from Frontier Biz: President
August 7, 2020
- Some Firms Curbing Supplies of Ethical Povidone-Iodine Products after Osaka COVID-19 Data
August 7, 2020
- Opdivo Eclipses Keytruda Again in July: Encise Drug Sales Ranking
August 7, 2020
- Sales Rep Promotions in June Double against May: Intage
August 7, 2020
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…